Morphine Sulphate Wockhardt

Quick links

Choose a section

Quick links to important sections

Advertisements

Morphine Sulphate Wockhardt

Advertisements
Advertisements

Overview of Morphine Sulphate Wockhardt

Quick Facts

Property Description
Active Ingredient Morphine Sulfate
Form Tablet, Extended-Release Tablet, Oral Solution, Injection
Pharmacological Class Opioid Agonist, Narcotic Analgesic
General Use Pain Management (Relief of severe pain)
Origin Naturally derived (Opium Alkaloid)

Core Identity: Morphine Sulphate and its Pharmacological Class

Morphine Sulphate Wockhardt is a prescription medication where the sole active ingredient is Morphine Sulfate, classified as a powerful Opioid Agonist and a Narcotic Analgesic. This pharmaceutical preparation, manufactured by Wockhardt, is clinically recognized for its high potency in managing severe discomfort. The drug is defined by its ability to modulate the pathways involved in pain perception, establishing it as one of the most effective agents for mitigating intense suffering.

Composition, Origin, and Pharmaceutical Form

The compound Morphine Sulfate is an organic substance derived from the opium poppy, classifying it chemically as an Opium Alkaloid and a Phenanthrene derivative. This core substance is processed into the stable salt form for medical use, resulting in a Single-ingredient product. This medication is indicated for the management of pain. Morphine Sulphate Wockhardt is available in various Dosage form(s), commonly including standard Tablet or an Extended-Release Tablet, designed primarily for Oral Route of administration. The availability of both immediate and extended-release options is a differentiating feature that allows clinicians to match the drug's delivery rate to the patient's pattern of pain.

General Purpose of This Analgesic Agent

The general purpose of this medication is to provide strong Analgesia for patients experiencing intense physical suffering that is typically unresponsive to non-opioid medications. It achieves this by directly engaging specific natural binding sites, known as μ-opioid receptors, in the brain and spinal cord. This mechanism allows the medication to significantly reduce the perception of pain, which is its core benefit in Pain Management. For example, it is frequently used in scenarios involving acute post-operative pain or pain associated with specific chronic illnesses. By altering the pain signals within the CNS, the medication fulfills its essential role as a high-potency analgesic agent.

Advertisements

What side effects are possible with Morphine Sulphate Wockhardt?

Possible Side Effects and Safety Information

The officially documented safety profile for Morphine Sulphate focuses on defining both expected, frequent adverse reactions and serious, less common systemic risks. All classifications and descriptions are based on authoritative government regulatory documents.

Adverse Reactions Classified by Frequency and System

Adverse reactions are categorized based on their documented incidence in clinical use, primarily affecting the gastrointestinal and nervous systems:

Classification System-Organ Class Focus Examples (Per Regulatory Labels)
Very Common Gastrointestinal, Nervous System Constipation, Nausea, Sedation, Drowsiness, Itching
Common Nervous System, General Disorders Headache, Vertigo, Urinary retention, Hypotension

The most frequently reported effects, often observed during treatment initiation, include constipation, nausea, somnolence, and dizziness.

Serious Adverse Reactions and Safety Constraints

The primary, life-threatening safety risk documented in regulatory labels is Respiratory Depression, which can lead to apnea or circulatory depression, shock, and cardiac arrest. Regulatory documents also highlight the intrinsic risks of Addiction, Abuse, and Misuse associated with long-term use, and the development of Tolerance and Physical Dependence.

Specific conditions are listed as Contraindications where the medication should not be used, including significant respiratory depression, unmonitored severe bronchial asthma, and known or suspected gastrointestinal obstructions, such as paralytic ileus.

Population-Specific Safety Notes

The official label contains explicit safety considerations for certain patient groups:

  • Elderly and Debilitated Patients: These individuals have an increased risk of severe respiratory depression.
  • Renal and Hepatic Impairment: Slower drug clearance in these patients may increase the risk of adverse effects and toxicity.
  • Pregnancy (Prolonged Use): There is a documented risk of Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn following prolonged use during pregnancy.

These official regulatory domains structure the understanding of the drug’s risks, defining the safety boundaries for its clinical use.

Advertisements

Overdose and Emergency Response

Overdose of Morphine Sulphate Wockhardt is defined by regulatory documents as an acute, potentially life-threatening event that necessitates immediate medical attention. The officially documented clinical signs of overdose center on severe Central Nervous System (CNS) and respiratory depression. Manifestations typically progress from extreme somnolence to stupor or coma, accompanied by key physiological signs such as miosis (pinpoint pupils), skeletal muscle flaccidity, and cold, clammy skin.

The primary hazard is profound respiratory depression, which can escalate to apnea (cessation of breathing) and severe cyanosis. Regulatory labeling states that severe overdose may lead to life-threatening outcomes, including circulatory collapse and cardiac arrest. Due to these severe risks, contacting emergency services is mandated upon any suspicion of overdose.

Management, as described in official prescribing information, is primarily symptomatic and supportive. A specific opioid antagonist, such as Naloxone, is documented to reverse the respiratory and CNS effects. Further required emergency actions include establishing a patent airway and utilizing assisted or controlled ventilation. For oral formulations, gastric lavage or activated charcoal may be considered if ingestion was recent. Continuous observation and hospital monitoring are necessary given the severity of the overdose syndrome.

Advertisements

Therapeutic Uses of Morphine Sulphate Wockhardt

What Morphine Sulphate Wockhardt Treats: Main Uses and Benefits

Morphine Sulphate Wockhardt is commonly used to help with the management of severe, acute, and chronic pain where use of a strong opioid analgesic is considered appropriate and for which alternative treatments are inadequate. This medication is relevant in clinical settings that involve acute or disruptive symptom patterns.

This therapeutic domain is applied across contexts where additional symptomatic support is needed to address symptoms related to physical discomfort that are intense or disruptive. The medication is commonly used for the treatment of severe pain associated with chronic conditions (like cancer), pain following major surgical procedures, and supportive management for severe shortness of breath (dyspnoea) in palliative care. It is relevant for easing intense symptomatic discomfort when discomfort has proven refractory to lower-potency treatments.

“It provides supportive relief that helps ease the overall symptom burden, particularly when pain is debilitating or persistent.”

This use contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability when acute manifestations disrupt daily routines.

Quick Fact: Symptomatic Support for Severe Discomfort
Primary Indication Severe Pain (used when symptoms become difficult to tolerate)
Palliative Benefit May assist with severe respiratory distress (dyspnoea)
Scenario Use Post-operative pain, Major trauma, Chronic illness
Advertisements

Eligibility and Restrictions for Use

Population Eligibility for Morphine Sulphate Wockhardt

The eligibility for using Morphine Sulphate Wockhardt is strictly defined by regulatory authorities and is classified into populations permitted, restricted, or absolutely prohibited from use.

Absolute Contraindications (Must Not Use)

The medicine is contraindicated in patients with a known hypersensitivity to morphine or its components. It must not be used by individuals experiencing severe respiratory depression, those with acute or severe bronchial asthma in an unmonitored setting, or patients with confirmed or suspected paralytic ileus or other gastrointestinal obstructions. Use is also restricted in cases of head injury or increased intracranial pressure.

Restricted and Conditional Use

Population Group Regulatory Status Condition
Severe Renal/Hepatic Impairment Use with Caution Required due to altered metabolism and risk of active metabolite accumulation.
Geriatric Patients Use with Caution May require a reduced initial dose due to increased sensitivity and risk.
Pregnant/Lactating Patients Not Recommended Prolonged use in pregnancy risks Neonatal Opioid Withdrawal Syndrome; excretion into breast milk may harm the infant.
Pediatric Patients Not Recommended/Contraindicated Extended-release formulations are generally not recommended or not established for those under 18 years of age.

Use is established primarily in adult patients requiring strong analgesia for severe pain.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Morphine Sulphate Wockhardt is defined by specific pharmacodynamic, pharmacokinetic, and procedural constraints documented by regulatory authorities.

Critical and Prohibited Combinations

Morphine Sulphate Wockhardt is formally contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs). This constitutes a mandatory timing restriction: the opioid must not be administered within 14 days of stopping MAOI therapy. A clinically significant interaction also occurs with Central Nervous System (CNS) Depressants, including benzodiazepines, sedatives, general anesthetics, and alcohol (ethanol). These agents cause an additive CNS depressant effect, increasing the risk of profound sedation and respiratory depression. Co-administration with Mixed Agonist/Antagonist Opioids (e.g., Pentazocine) should be avoided as it may reduce the analgesic effect or precipitate withdrawal symptoms.

Exposure Modification and Procedural Constraints

The profile details substances that alter drug exposure. Cimetidine and P-glycoprotein (P-gp) Inhibitors may lead to higher plasma concentrations of morphine due to decreased metabolism or increased absorption. Conversely, Rifampicin can reduce the serum concentration of the drug. Procedural constraints include a recommendation for an at least two-hours interval between taking oral formulations and Antacids. Furthermore, the co-administration of morphine and Oral P2Y12 Inhibitors results in delayed and decreased exposure to the antiplatelet agent.

Advertisements

Mechanism of Action

Morphine Sulphate Wockhardt acts through highly specific biological mechanisms that interact with signaling pathways in the nervous system, focusing on key regulatory systems to influence signaling intensity within specific pathways.

Engaging Mu-Opioid Receptor Pathways

This mechanism centers on the mu-opioid receptor (mu-OR), concentrated in central pathways that mediate nociceptive transmission. The molecule acts as an agonist (activator) at this receptor, initiating a cascade that directly influences core mechanisms underlying sensory transmission.

Modulating Neural Signal Transduction

Activation of the mu-OR is coupled to inhibitory G-proteins, altering the electrical and chemical dynamics of target neurons. This cascade stabilizes the neuronal membrane by influencing ion channels (specifically opening potassium channels and closing voltage-gated calcium channels), leading to hyperpolarization and a reduction in the release of pro-nociceptive neurotransmitters. This results in a change in local mediator activity levels.

Altering Downstream Nociceptive Activity

The resulting physiological effect is the modulation of signal transmission in ascending nociceptive pathways and the activation of descending inhibitory pathways. This process involves the alteration of signaling dynamics within targeted pathways, resulting in changes to the overall intensity of pathway activity.

Advertisements

Dosage and Administration Information

Morphine Sulphate Wockhardt is administered via the oral route (as immediate-release or extended-release tablets and solutions) or through parenteral routes (injection, including intravenous, intramuscular, and subcutaneous administration). The selection of the formulation determines the prescribed frequency: immediate-release oral forms are generally initiated at a starting dose of 10 mg to 30 mg, scheduled for administration every 4 hours as needed. In contrast, extended-release tablets are designated for daily, around-the-clock therapy on a fixed schedule, typically every 8 or 12 hours, starting at 15 mg for opioid-naïve individuals.

The medication requires specific procedural handling. Extended-release tablets must be swallowed whole and should never be crushed, chewed, or dissolved, as altering the tablet compromises the controlled-release mechanism and may cause rapid release. Highly concentrated oral solutions (e.g., 100 mg/5 mL) are generally reserved for patients who are already defined as opioid-tolerant. Dosing across all forms must be individually titrated (adjusted) according to the patient's response. Specific populations, such as older adults or those with renal or hepatic impairment, typically require starting treatment at reduced dosages.

Upon conclusion of treatment, the dose must be gradually reduced over time to prevent issues related to physical dependence; abrupt cessation is generally not recommended.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Morphine Sulphate Wockhardt

Overview of Evidence Supporting Pain Management

The research base for the active ingredient, morphine sulfate, includes numerous Randomized Controlled Trials (RCTs) and systematic reviews which regulatory agencies reviewed for the management of severe acute and chronic pain. These studies were conducted to explore how outcomes related to physical discomfort change over time. Researchers examined adults with severe acute pain (like post-operative settings) and chronic pain. Findings describe patterns where differences in pain intensity scores were measured compared to baseline or a placebo. Bioequivalence studies for specific oral formulations, including Morphine Sulphate Wockhardt, were conducted to ensure comparable drug delivery to the bloodstream.

Evidence for Symptomatic Support of Severe Shortness of Breath (Dyspnoea)

Morphine sulfate was evaluated in research exploring its potential use in addressing severe, refractory shortness of breath (dyspnoea), particularly for patients receiving palliative care for advanced chronic illness. These studies, typically small-scale, often crossover trials, examined outcomes by measuring the intensity of the patient's subjective feeling of breathlessness using rating scales. Trials consistently reported patterns related to how symptoms evolved, including differences in the perceived intensity of breathlessness, when the compound was associated with the specific regimens studied.

Duration of Study and Limitations

For acute, short-term pain, research explored changes over defined time intervals measured in hours and days, and findings indicate that differences in reported symptoms are observed quickly. For chronic pain, controlled clinical trials extending beyond one year are limited. Long-term effects are not fully established because many controlled trials face the challenge of high patient dropout rates, relying instead on longer observational settings.

Evidence quality varies across studies. The certainty remains low for the dyspnoea indication due to small sample sizes and heterogeneous study designs. In all cases, results apply only to the populations studied and do not determine whether an individual will respond similarly.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Morphine Sulphate Wockhardt (FAQ)

Q: What is the main difference between Wockhardt's morphine and other pain pills?

Morphine Sulphate is classified by regulatory authorities as a potent Opioid Agonist and a Narcotic Analgesic designated for severe pain. This class of medicine works by directly activating specific opioid receptors in the central nervous system. This pharmacological action and potency differ significantly from non-opioid pain relievers, such as acetaminophen or ibuprofen.

Q: How quickly does Morphine Sulphate Wockhardt usually start working?

The time it takes to start working is generally dependent on the specific formulation being used. Official product information indicates that the peak analgesic effect from an immediate-release oral dose typically occurs within approximately 60 minutes. Injectable forms of the medication are known to have a faster onset of action.

Q: What is the expected duration of pain relief from this medicine?

According to official documentation, the duration of pain relief for immediate-release oral forms usually lasts 4 to 6 hours. The extended-release tablets are specifically designed to provide relief over a longer period, generally administered every 8 or 12 hours as part of a fixed schedule.

Q: Do I need to eat food when I take Morphine Sulphate Wockhardt?

Official studies on some extended-release formulations indicate that taking the tablet with a high-fat meal resulted in no significant difference in the amount of drug absorbed by the body compared to taking it on an empty stomach. The specific administration conditions depend on the exact form being used.

Q: Can Morphine Sulphate Wockhardt be taken with Tylenol or ibuprofen?

Official information from government health services indicates that it is generally safe to combine morphine with paracetamol (Tylenol), ibuprofen, or aspirin. However, due to the high number of potential interactions, it is necessary to discuss the use of all over-the-counter medications and supplements with a healthcare provider.

Q: Does Morphine Sulphate Wockhardt cause dependence if used as prescribed?

The medication carries an intrinsic risk of Physical Dependence with long-term use, even when taken exactly as directed. Physical dependence is a normal biological adaptation to the continuous presence of the drug in the body. It is an expected physiological effect that is distinct from the compulsive drug-seeking behavior defined as addiction.

Q: Can I take Morphine Sulphate Wockhardt if I have kidney problems?

Patients with severe renal impairment (kidney problems) should be treated with caution and may require reduced starting dosages. This is because slower clearance in these patients can increase the risk of adverse effects and toxicity due to the build-up of the medicine in the body.

Q: Are there any specific activities or machines I should avoid while taking this?

Official regulatory warnings state that the medicine can cause sedation, dizziness, and lightheadedness. Patients are advised to avoid activities requiring mental alertness, such as driving a car or operating hazardous machinery, until they know how the medication affects their coordination and reaction time.

Q: What is known about using this drug during pregnancy?

Official labeling states that prolonged use of this opioid during pregnancy may cause fetal harm. There is a documented risk of the newborn developing Neonatal Opioid Withdrawal Syndrome (NOWS). The medicine is not recommended for use during pregnancy.

Q: How does this medicine affect people who are over 65 years old?

Geriatric patients may have increased sensitivity to the drug and a greater risk of experiencing severe respiratory depression. Regulatory guidelines recommend that these individuals typically require starting treatment at reduced dosages and should be closely monitored.

Q: What are the official recommendations regarding alcohol and this medicine?

Official warnings strongly advise that concomitant use of opioids with alcohol may result in profound sedation, respiratory depression (slowed breathing), coma, and death. Patients are explicitly advised to avoid use of alcohol or medications that contain alcohol while taking this medicine.

Q: Is Morphine Sulphate Wockhardt effective for nerve pain?

Research reviewed by official bodies regarding the efficacy of oral morphine for chronic neuropathic pain is of very low quality. This evidence theme means that the available data does not reliably indicate whether the drug provides a substantial benefit for chronic pain stemming from nerve issues.

Q: What should be done if an interaction with another medicine is suspected?

Official patient counseling information emphasizes the importance of providing a complete and up-to-date list to your healthcare provider. This list should include all other medications, including any herbal remedies, vitamins, and supplements you are taking.

Q: Does the Wockhardt brand have any known differences from other manufacturers?

Regulatory documents confirm that bioequivalence studies are conducted to ensure that different brands of the active ingredient (morphine sulfate) deliver a comparable amount of drug to the bloodstream. Any differences between brand manufacturers may relate only to the product's packaging, availability, or available strengths.

Q: Are there any known drug interactions that can cause serotonin syndrome?

Yes, official labels explicitly warn that the concomitant use of opioids with certain serotonergic drugs may result in a condition called serotonin syndrome. If this is suspected, regulatory guidance is to discontinue the morphine sulfate tablets.

Q: What information is available about taking this medicine while breastfeeding?

Official guidance generally states that the medicine is not recommended while breastfeeding. Regulatory labels note that morphine is excreted into breast milk and has the potential to cause serious adverse reactions in a nursing infant.

Q: Does Morphine Sulphate Wockhardt interact with any common herbal supplements?

Official health resources caution that it is not possible to state that herbal remedies or supplements are safe to take with morphine. This is because most herbal products are not routinely tested for their interaction effects on prescription medications.

Q: How long after stopping the medication is it considered out of the system?

The time it takes for a drug to clear the body is related to its half-life, which for morphine typically falls between 1.5 and 4.5 hours. While the effects subside sooner, the drug and its metabolites can often be detected in the urine for 1 to 3 days after the last dose.

Q: Is it possible to become tolerant to the pain-relieving effects?

Yes, the development of Tolerance is an intrinsic risk associated with continuous opioid use. Official product information notes that tolerance means a person may require a higher dose of the drug over time to achieve the same therapeutic effect of pain relief.

Q: What is the evidence theme regarding its use for chronic non-cancer pain?

Regulatory bodies and guidelines acknowledge that there is insufficient evidence to reliably determine the long-term benefits of opioid therapy for chronic non-cancer pain. Additionally, official guidelines note an increased risk for serious harms related to the long-term use of these medications.

Q: What is the difference between pain relief and sedation with this drug?

The analgesia (pain relief) is the intended therapeutic effect and the primary purpose of the medicine's mechanism of action. In contrast, sedation is listed separately in official labels as a very common adverse reaction or side effect, indicating it is an unintended effect, not the primary therapeutic goal.

Q: Can people with a history of substance use disorder use this drug?

Official guidance lists a history of alcohol abuse and drug dependence as medical problems for which the medicine should be used with caution. This indicates that a history of substance use is not an absolute prohibition but requires careful consideration and monitoring.

Q: Are there common drug-drug interactions with antidepressants?

Yes, official labels explicitly warn about interactions with serotonergic drugs, a category that includes common antidepressants such as SSRIs and SNRIs. Concomitant use with these medications may lead to the serious condition known as serotonin syndrome.

Q: Why is this drug sometimes used in palliative care?

In addition to its use for severe pain, the drug has been evaluated in research exploring its potential for managing severe, refractory shortness of breath (dyspnoea). This use, particularly in patients receiving palliative care for advanced chronic illness, is mentioned in research overviews.

Advertisements

How should Morphine Sulphate Wockhardt be stored and disposed of?

Official Storage and Disposal Requirements

Storage Condition Type: Controlled room temperature (below 25 C) / Protect from light
In-Use Stability Classification: Use within 3 to 4 months after first opening (Oral Solution)
Child-Protection Storage: Keep out of the sight and reach of children

Morphine Sulphate Wockhardt must be stored at or below 25 C and kept in its original container to protect it from light. The Oral Solution has a limited use period of 3 to 4 months once the bottle is opened. As a highly potent opioid, the medication must be stored securely out of the sight and reach of children due to the risk of a fatal overdose from accidental ingestion. For disposal, unused or expired product should not be thrown into household waste or flushed when take-back programs or other authorized destruction methods are available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Morphine Sulphate Wockhardt found in:

A-Z Index: